Open | - |
Close | - |
Volume / Avg. | 229.000 / 1.836M |
Day Range | - - - |
52 Wk Range | 0.420 - 2.050 |
Market Cap | $357.896M |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 51 |
Short Interest | 2.72% |
Days to Cover | 1.44 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Adaptimmune Therapeutics (NASDAQ: ADAP) through any online brokerage.
Other companies in Adaptimmune Therapeutics’s space includes: Adverum Biotechnologies (NASDAQ:ADVM), Precigen (NASDAQ:PGEN), Inozyme Pharma (NASDAQ:INZY), Anika Therapeutics (NASDAQ:ANIK) and TScan Therapeutics (NASDAQ:TCRX).
The latest price target for Adaptimmune Therapeutics (NASDAQ: ADAP) was reported by Barclays on Thursday, August 10, 2023. The analyst firm set a price target for 1.00 expecting ADAP to fall to within 12 months (a possible -31.03% downside). 7 analyst firms have reported ratings in the last year.
The stock price for Adaptimmune Therapeutics (NASDAQ: ADAP) is $1.45 last updated Today at March 19, 2024 at 7:14 AM EDT.
There are no upcoming dividends for Adaptimmune Therapeutics.
Adaptimmune Therapeutics’s Q1 earnings are confirmed for Friday, May 10, 2024.
There is no upcoming split for Adaptimmune Therapeutics.
Adaptimmune Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.